

---

## **STRIDES ARCOLAB RECEIVES US FDA APPROVAL FOR METHOTREXATE INJECTION**

---

**March 30, 2012 Bangalore:** Onco Therapies Limited, a wholly owned subsidiary of Strides Arcolab Limited (Strides) today announced that it has received US FDA approvals for ***Methotrexate Injection*** USP 25 mg/ mL packaged in 1 gram/ 40 mL, 50 mg/2 mL, 100 mg / 4 mL, 200 mg/ 8 mL and 250 mg / 10 mL Single dose vials (preservative-free)

Methotrexate is amongst the products in the drug shortage list of US FDA. According to IMS data, the US market for generic Methotrexate is approximately USD 13 Million.

Methotrexate is part of the Oncology portfolio licensed to Pfizer in January 2010 for the US market and expected to be launched shortly.

### **About Methotrexate**

Methotrexate is a chemotherapy drug used either alone or in combination with other agents. It is used as a treatment for some autoimmune diseases including: rheumatoid arthritis, psoriasis, psoriatic arthritis, lupus and Crohn's disease, to name a few.

### **About Agila Specialties**

Agila is the specialties unit of Strides Arcolab which was spun off as a separate division post the Company's restructuring in 2009. It is focused on key domains such as oncolytics, penems, penicillins, cephalosporins, ophthalmics, peptides and biosimilars and operates from 8 world-class global manufacturing facilities, including one of the largest steriles capacity in India and amongst the largest lyophilization (freeze drying) capacities in the world. Agila's marketing network covers 70 countries and it has partnerships with some of the world's leading pharmaceutical companies for both developed and emerging markets.



## **About Strides Arcolab Limited**

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 13 manufacturing facilities across 5 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.

Additional information is available at the company's website at [www.stridesarco.com](http://www.stridesarco.com).

For further information, please contact:

| <b><u>Strides</u></b>                                                              | <b><u>PR Consultancy</u></b>                                                                                        |
|------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|
| Mr. V.S. Iyer, CEO - Agila<br>+91 80 6784 0111                                     | Corporate Voice   Weber Shandwick                                                                                   |
| Mr. Ajay Singh : +91 80 6784 0813<br>Mr. Kannan N : +91 98450 54745<br>(Investors) | Mahesh Nair,<br>+91 9880376648<br><a href="mailto:maheshn@corvoshandwick.co.in">maheshn@corvoshandwick.co.in</a>    |
|                                                                                    | Kaveri Mandanna,<br>+91 90089 59697<br><a href="mailto:kaveri@corvoshandwick.co.in">kaveri@corvoshandwick.co.in</a> |

